Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China
Location status: Recruiting
Location contact
Nan Li, MD
CONTACT
Xin Zhou, MD
CONTACT
NCT Number: NCT06648317
To evaluate the ability of [68Ga]N188 to detect nectin-4 overexpression in patients with lung lesions.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Beijing, Beijing Municipality, 100142, China
Location status: Recruiting
Nan Li, MD
CONTACT
Xin Zhou, MD
CONTACT
To evaluate the ability of [68Ga]N188 to detect nectin-4 overexpression in patients with different lung lesions, such as inflammation and lung cancer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All study participants will undergo 18F-FDG PET/CT scan within 1 week
Time frame: 1 year
SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions. The uptake of the tracer (68Ga-N188) in lung lesions by measuring SUV on PET/CT.
Contact information is provided by the study sponsor or research team.
Peking University Cancer Hospital & Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05628376
Adenoma, Bronchial Neoplasms
London, United Kingdom
View Trial DetailsNCT07561567
Bronchial Neoplasms, Carcinoma, Bronchogenic
Tianjin, China
View Trial DetailsNCT06687408
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hangzhou, China
View Trial DetailsNCT07219251
Adenocarcinoma, Adenocarcinoma of Lung
Palo Alto, California, United States
View Trial Details